A

Adjuvant systemic primary breast cancer therapy, 199-226. See also Breast cancer
Benefit evaluation, 200-203
Candidates for, 216-221
Chemotherapy and radiation therapy sequencing, 214-215
Chemotherapy dose intensity, 214
Chemotherapy toxicity, 215-216
Chemotherapy trial results, 205
Combined hormone and chemotherapy, 211-213
Duration factors, 209-211
Hormone therapy , 211, 215
Immunotherapy, 213-214
Investigation areas, 221-222
Optimal chemotherapy regimens, 206
Ovarian ablation trial results, 204
Overview, 199-200
Primary invasive breast cancer surgery, recurrence factors, 285
Tamoxifen benefits, 216
Tamoxifen trial results, 204
World overview of trials, generally, 203-204

Alcohol consumption
Oral and oropharyngeal squamous cancers, 329-332

American Cancer Society
Acknowledgment 1993-1994, 112-113
Acknowledgment 1995, 377
Cervical cancer early detection guidelines, 314
Clinical Awards, 192
Clinical Oncology Social Work Training Grants, 256
Cytotechnology Training Grants, 147
Highlights of National Conference on Gynecologic Cancers, 254-255
National Conference on Colorectal Cancer, 256

Announcements
American Cancer Society Clinical Awards, 192
American Cancer Society Cytotechnology Training Grants, 147
International Union Against Cancer World Conference for Cancer Organisations, 243, 376

Anthracyclines
Adjuvant systemic primary breast cancer therapy, 206-209

Assay variability
Prostate-specific antigen (PSA), 160-161

Axillary lymph nodes
Primary invasive breast cancer surgery, 285-286

B

Bilateral salpingo-oophorectomy
Epithelial ovarian cancer metastasis, 89

Biopsy
Oral and oropharyngeal squamous cancers, 348-349
Prostate-specific antigen (PSA) screening, 161

Brachytherapy (for prostate cancer), 165-178
Clinical results, 173-176
Historical background, 166
Isotopes, 169-172
Methods, generally, 166-167
Overview, 165-166
Retropubic technique, 167-168
Temporary implantation, 169
Transperineal technique, 168-169

Breast cancer
Adjuvant systemic primary breast cancer therapy, 199-226
Ductal carcinoma in situ, 244-253
The Foremost Cancer—Revisited, 197-198 (Editorial)
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)
Primary chemotherapy in surgically resectable breast cancer, 227-243
Primary invasive breast cancer surgery, 279-288
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)

Breast cancer patient advocacy, 114-126
Adjuvant therapy, 120-121
Employment and insurance problems, 122-124
Issues, generally, 115-118, 123
Overview, 114
Patient-physician communication, 118-119
Primary treatment choice, 119-120
Providers involved in, 124
Psychosocial issues, 121-122
Rationale, 115
Reconstructive surgery, 120

Breast cancer risk evaluation and management, 263-278
Current approach, 275-276
Overview, 263
Prophylactic mastectomy, 268-275
Risk factors, 263-268

Breast reconstruction, 289-304
Breast cancer patient advocacy, 119, 120
Implants, 293-295
Management team, 290
Overview, 289-290
Reach to Recovery Program, 290
Techniques, 295-303
Timing and selection, 291-293
Treatment role, 290-291

Breast self-examination
Prophylactic mastectomy alternatives, 273

C

California Tobacco Control Program, 369-372

Cancer Statistics, 8-30
Incidence, 11, 12, 14, 16
Mortality, 11, 13, 15, 17, 18-24, 28-29
Overview, 8-10
Stage at diagnosis, 26
Survival rates, 25, 27, 30

A

Adjuvant systemic primary breast cancer therapy, 199-226. See also Breast cancer
Benefit evaluation, 200-203
Candidates for, 216-221
Chemotherapy and radiation therapy sequencing, 214-215
Chemotherapy dose intensity, 214
Chemotherapy toxicity, 215-216
Chemotherapy trial results, 205
Combined hormone and chemotherapy, 211-213
Duration factors, 209-211
Hormone therapy , 211, 215
Immunotherapy, 213-214
Investigation areas, 221-222
Optimal chemotherapy regimens, 206
Ovarian ablation trial results, 204
Overview, 199-200
Primary invasive breast cancer surgery, recurrence factors, 285
Tamoxifen benefits, 216
Tamoxifen trial results, 204
World overview of trials, generally, 203-204

Alcohol consumption
Oral and oropharyngeal squamous cancers, 329-332

American Cancer Society
Acknowledgment 1993-1994, 112-113
Acknowledgment 1995, 377
Cervical cancer early detection guidelines, 314
Clinical Awards, 192
Clinical Oncology Social Work Training Grants, 256
Cytotechnology Training Grants, 147
Highlights of National Conference on Gynecologic Cancers, 254-255
National Conference on Colorectal Cancer, 256

Announcements
American Cancer Society Clinical Awards, 192
American Cancer Society Cytotechnology Training Grants, 147
International Union Against Cancer World Conference for Cancer Organisations, 243, 376

Anthracyclines
Adjuvant systemic primary breast cancer therapy, 206-209

Assay variability
Prostate-specific antigen (PSA), 160-161

Axillary lymph nodes
Primary invasive breast cancer surgery, 285-286

B

Bilateral salpingo-oophorectomy
Epithelial ovarian cancer metastasis, 89

Biopsy
Oral and oropharyngeal squamous cancers, 348-349
Prostate-specific antigen (PSA) screening, 161

Brachytherapy (for prostate cancer), 165-178
Clinical results, 173-176
Historical background, 166
Isotopes, 169-172
Methods, generally, 166-167
Overview, 165-166
Retropubic technique, 167-168
Temporary implantation, 169
Transperineal technique, 168-169

Breast cancer
Adjuvant systemic primary breast cancer therapy, 199-226
Ductal carcinoma in situ, 244-253
The Foremost Cancer—Revisited, 197-198 (Editorial)
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)
Primary chemotherapy in surgically resectable breast cancer, 227-243
Primary invasive breast cancer surgery, 279-288
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)

Breast cancer patient advocacy, 114-126
Adjuvant therapy, 120-121
Employment and insurance problems, 122-124
Issues, generally, 115-118, 123
Overview, 114
Patient-physician communication, 118-119
Primary treatment choice, 119-120
Providers involved in, 124
Psychosocial issues, 121-122
Rationale, 115
Reconstructive surgery, 120

Breast cancer risk evaluation and management, 263-278
Current approach, 275-276
Overview, 263
Prophylactic mastectomy, 268-275
Risk factors, 263-268

Breast reconstruction, 289-304
Breast cancer patient advocacy, 119, 120
Implants, 293-295
Management team, 290
Overview, 289-290
Reach to Recovery Program, 290
Techniques, 295-303
Timing and selection, 291-293
Treatment role, 290-291

Breast self-examination
Prophylactic mastectomy alternatives, 273

C

California Tobacco Control Program, 369-372

Cancer Statistics, 8-30
Incidence, 11, 12, 14, 16
Mortality, 11, 13, 15, 17, 18-24, 28-29
Overview, 8-10
Stage at diagnosis, 26
Survival rates, 25, 27, 30

Cervical cancer
Papanicolaou smear, 305-320

Cervical esophagus
Head and neck cancer treatment, 360-361

Cervical lymph nodes
Head and neck cancer, 354, 363-364

Chemoprevention, 31-49
Agents, 32-33, 38, 39
Biomarkers, 40-41
Future trends, 46-47
Genetic mechanism targeting, 33, 36-37
Group targeting, 46
NCI program, 37-40
Overview, 31-32
Trials, 34-35, 41-46

Chemotherapy
Adjuvant systemic primary breast cancer therapy, 205, 206
Adjuvant systemic primary breast cancer therapy, combined hormone therapy, 211-213
Adjuvant systemic primary breast cancer therapy, dose intensity, 214
Adjuvant systemic primary breast cancer therapy, radiation therapy sequencing, 214-215
Colorectal metastases to liver, 51, 53, 56, 57
Epithelial ovarian cancer treatment, 91-99
Primary, in surgically resectable breast cancer, 227-243

Chlorambucil
Epithelial ovarian cancer treatment, 92, 94

Cigarette smoking
Oral and oropharyngeal squamous cancers, 329-332
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)
Tobacco use prevention and cessation, 369-374

Cisplatin
Epithelial ovarian cancer treatment, 91-95
Primary chemotherapy in surgically resectable breast cancer, 230

Clinical breast examination
Prophylactic mastectomy alternatives, 273-275

Colorectal cancer
AJCC report, 107
Genetics, 36, 37
Perspectives on Cancer Prevention, 6 (Guest Editorial)

Colorectal liver metastases, 50-62
Cryosurgery, 56-58
Medical treatment, 51, 53
Natural history, 50-51, 52
Overview, 50
Regional infusion therapy, 58-60
Surgical resection, 51-52, 54-56
Vascular interruption, 60

Combined hormone and chemotherapy
Adjuvant systemic primary breast cancer therapy, 211-213

Cryosurgery
Colorectal liver metastases, 56-58

Cyclophosphamide
Adjuvant systemic primary breast cancer therapy, 205, 207, 209
Epithelial ovarian cancer treatment, 92-95, 98
Primary chemotherapy in surgically resectable breast cancer, 229

D

Digital rectal examination (DRE)
Prostate cancer screening, 137, 138, 139, 150

Doxorubicin
Adjuvant systemic primary breast cancer therapy, 206, 207, 209
Epithelial ovarian cancer treatment, 94, 95

Ductal carcinoma in situ, 244-253
Future studies, 252
Malignant potential, 246-247
Management approach, 250-251
Overview, 244
Pathology, 245-246
Presentation, 244-245
Treatment options, 247-250
Treatment recommendations, 251-252

Dysplasia
Oral and oropharyngeal squamous cancers, 341-343

E

Early detection
Early Diagnosis and Treatment of Head and Neck Cancer, 325-327 (Guest Editorial)
Head and neck cancer, 353
Oral and oropharyngeal squamous cancers, 328-351
Ovarian cancer, 71-87
Papanicolaou smear, 305-320
Prostate cancer screening, 134-147
Prostate-specific antigen (PSA), 148-164

Editorials
Early Diagnosis and Treatment of Head and Neck Cancer, 325-327(Guest Editorial)
The Foremost Cancer—Revisited, 197-198
Ovarian Cancer, 69-70 (Guest Editorial)
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)
Prostate Cancer: Here and Now, 133
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)

Employment problems
Breast cancer patient advocacy, 122-124

Epidemiology
Cancer statistics, 8-30
Prostate cancer screening, 142-145

Epirubicin
Adjuvant systemic primary breast cancer therapy, 206
Epithelial ovarian cancer treatment, 94
Primary chemotherapy in surgically resectable breast cancer, 230, 231

Epithelial ovarian cancer
Advanced-stage disease, 93-99
Early-stage disease, 89, 91-93
Epithelial ovarian cancer treatment, 88-101
Ovarian cancer detection, 73
Overview, 88
Surgery and staging, 88-89

Errata
Cancer Statistics, 1995, 127-128

Erythroplasia
Oral and oropharyngeal squamous cancers, 336-338

Esophageal cancer
Head and neck cancer treatment, 360-361
Risk factors, 329

Etoposide
Epithelial ovarian cancer treatment, 94, 95

Extensive intraductal component
Primary invasive breast cancer surgery, recurrence factors, 284

F

Familial cancer
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)

Family history
Breast cancer risk evaluation, 264
Ovarian cancer detection, 75

Fertility
Breast cancer patient advocacy, 121

Fibrocystic disease
Breast cancer risk evaluation, 267

Finasteride
Chemoprevention, 33

5-Fluorouracil (5-FU)
Adjuvant systemic primary breast cancer therapy, 205, 209
Colorectal metastases to liver, 51
Epithelial ovarian cancer treatment, 94, 95
Primary chemotherapy in surgically resectable breast cancer, 229, 230

G

Genetics
Breast cancer risk evaluation, 264-266
Chemoprevention, 33, 36-37
Ovarian cancer, 69-70 (Guest Editorial)
Ovarian cancer detection, 75-76, 79-80

Glisson's capsule
Epithelial ovarian cancer metastasis, 88, 89
Gluteus maximus musculocutaneous flap breast reconstruction techniques, 302-303

H

Head and neck cancer
Cervical lymph node management, 363-364
Cervical lymph nodes, 354
Clinical diagnosis, 353
Early Diagnosis and Treatment of Head and Neck Cancer, 325-327 (Guest Editorial)
Follow-up care and prevention, 365-366
Larynx, hypopharynx, and cervical esophagus treatment, 360-361
Oral and oropharyngeal squamous cancers, early detection, 328-351
Oral cavity treatment, 358-359
Overview, 352-353
Paranasal sinus treatment, 361-363
Pharynx treatment, 359-360
Radiation therapy, 364-365
Reconstruction and rehabilitation, 365
Salivary gland treatment, 363
Staging, 354-355
Treatment alternatives, 356
Treatment goals, 355-356
Treatment selection, 356-358

Health insurance
Breast cancer patient advocacy, 122-124

Hepatic artery infusional (HAI) chemotherapy
Colorectal metastases to liver, 56, 59

Hepatic artery ligation (HAL)
Colorectal liver metastases, 60

Hexamethylmelamine
Epithelial ovarian cancer treatment, 94, 95

Hormone therapy
Adjuvant systemic primary breast cancer therapy, 211
Adjuvant systemic primary breast cancer therapy, combined chemotherapy, 211-213
Adjuvant systemic primary breast cancer therapy, toxicity, 211-213
Chemoprevention, 33
Prostate cancer, 166
Prostate cancer screening, 137

Hypopharynx
Head and neck cancer treatment, 360-361

I

Ifosfamide
Epithelial ovarian cancer treatment, 95-96

Immunotherapy
Adjuvant systemic primary breast cancer therapy, 213

Implants
Breast reconstruction, 293-295

Intraperitoneal chemotherapy
Epithelial ovarian cancer treatment, 96-97

L

Larynx
Head and neck cancer treatment, 360-361

Latissimus dorsi musculocutaneous flap
Breast reconstruction techniques, 302

Leucovorin
Colorectal metastases to liver, 51

Leukoplakia
Oral and oropharyngeal squamous cancers, 338-341

Liver metastatic disease
Colorectal metastases to liver, 50-62

Lobular carcinoma in situ
Breast cancer risk evaluation, 267

Low malignant potential (LMP) tumor
Ovarian cancer detection, 73, 74

Lung cancer
Genetics, 36
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)

Lymph nodes
Epithelial ovarian cancer metastasis, 88, 89
Head and neck cancer, 354, 363-364
Primary invasive breast cancer surgery, recurrence factors, 283

M

Mammography
Prophylactic mastectomy alternatives, 273-275

Mastectomy
Breast cancer patient advocacy, 119
Breast reconstruction, 289-304
Ductal carcinoma in situ, 247-250
Primary invasive breast cancer surgery, 279-288
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)

Melphalan
Adjuvant systemic primary breast cancer therapy, 205
Epithelial ovarian cancer treatment, 91, 92, 94

Metastatic disease
Adjuvant systemic primary breast cancer therapy, 206
Breast cancer, primary chemotherapy, 227, 228
Colorectal metastases to liver, 50-62
Epithelial ovarian cancer, 88, 89

Methotrexate
Adjuvant systemic primary breast cancer therapy, 205
Epithelial ovarian cancer treatment, 94
Primary chemotherapy in surgically resectable breast cancer, 229, 231

Mitomycin
Epithelial ovarian cancer treatment, 94
Primary chemotherapy in surgically resectable breast cancer, 231

Mitoxantrone
Epithelial ovarian cancer treatment, 94

Modified radical mastectomy
Breast cancer patient advocacy, 119

Molecular biomarkers
Ovarian cancer detection, 79-80, 81

MYCN oncogene amplification
Neuroblastoma, 180

Myelosuppression
Epithelial ovarian cancer treatment, 95

N

The National Cancer Data Base clinical highlights, 102-111
Breast cancer, 108
Characteristics, 104-105
Colorectal cancer, 107
Data presentation, 106
Data sources, 102-103, 106
Laryngeal cancer, 109
Overview, 102
Pancreatic cancer, 111
Prostate cancer, 110
Thyroid cancer, 11

Neuroblastoma, 179-192
Disease sites, 182-183
Epidemiology, 179-180
Evaluation, 183-184
Overview, 179
Pathophysiology, 180-182
Prognostic factors, 185
Signs and symptoms, 182
Staging, 184-185
Treatment, 185-189

Nipple-areola reconstruction
Breast reconstruction techniques, 303

Nutrition and diet
Chemoprevention, 31-33, 43-45
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)

O

Oral and oropharyngeal squamous cancers, 328-351
Biopsy, 348-349
Dysplasia, carcinoma-in-situ and invasive carcinoma, 341-343
Erythroplasia, 336-338
Intraoral examination, 335-336
Lesion workup, 348
Leukoplakia, 338-341
Overview, 328-329

Risk factors, 329-332
Risk sites, 332-334
Staging, 343-344
Vital staining, 345-348

Oral cavity
Head and neck cancer treatment, 358-359

Orchiectomy
Prostate cancer, 166

Ovarian ablation
Adjuvant systemic primary breast cancer therapy, 204

Ovarian Cancer, 69-70 (Guest Editorial)

Ovarian cancer detection, 71-87
Biochemical markers, 77-79
Biostatistical considerations, 74-75
Clinical applications, 80-83
Imaging modalities, 76-77
Molecular biomarkers, 79-80, 81
Overview, 71-73
Pathologic entity, 73-74
Patient history and physical examination, 75-76

Ovarian cancer treatment. See Epithelial ovarian cancer

P

Paclitaxel
Epithelial ovarian cancer treatment (advanced stage), 94, 96-99

Pancreatic cancer
Genetics, 36

Papanicolaou smear, 305-320
Accuracy of, 310-311
Adequacy of, 309-310
Atypical cells, 307-309
Automation of, 312-313
Clinical considerations, 315
Cytologic nomenclature, 306-307
Economic factors, 317-318
Human resources for, 312
Management guidelines, 315-316
Medicolegal/CLIA aspects, 316-317
Overview, 305-306
Screening guidelines and intervals, 313-315

Paranasal sinus
Head and neck cancer treatment, 361-363

Patient-physician communication
Breast cancer patient advocacy, 118-119

Pharynx
Head and neck cancer treatment, 359-360

Ploidy
Neuroblastoma, 180

Postmenopausal palpable ovary syndrome
Ovarian cancer detection, 75

Prednisone
Adjuvant systemic primary breast cancer therapy, 205
Primary chemotherapy in surgically resectable breast cancer, 229

Pregnancy
Breast cancer risk evaluation, 266

Prevention
Perspectives on Cancer Prevention, 5-7 (Guest Editorial)

Primary chemotherapy in surgically resectable breast cancer, 227-243. See also Breast cancer
Background, 228-229
Chemotherapy and radiation therapy sequence, 240-241
Early clinical trials, 229-232
Experimental basis, 227-228
Milan Cancer Institute trials, 232-235
Overview, 227
Recent randomized trials, 235-237
Surgical management selection, 237-240

Primary invasive breast cancer surgery, 279-288
Axillary lymph nodes, 285-286
Breast-conserving treatment, 280-281
Contraindications, 281
Overview, 279
Radiation therapy, 280-281
Recurrence factors, 281-285
Survival for early-stage cancer, 279-280

Prophylactic mastectomy. See also Breast cancer
Alternatives to, 273-275
Generally, 268-270
Indications for, 271-273
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)
Technique, 270-271

Prostate cancer
Brachytherapy, 165-178
Chemoprevention, 33, 43
Prostate Cancer: Here and Now, 133 (Editorial)

Prostate cancer screening, 134-147
Epidemiologic evidence supporting, 142-145
Evidence supporting, generally, 138-139
Overview, 134-135
Pathologic evidence supporting, 139-142
Prostate-specific antigen (PSA), 148-164
Rationale, 135-138

Prostate-specific antigen (PSA), 148-164
Assay variability, 160-161
Background, 148-149
Digital rectal examination (DRE) and, 150
Issues, 161-162
Overview, 148
Prostate cancer screening, 135, 137, 138, 139
Repeat biopsy requirement, 161
Specificity enhancement, 150-160
Standardization, 161
Strategy evaluation, 149-150

Psychosocial issues
Breast cancer patient advocacy, 121-122

R

Radiation therapy
Adjuvant systemic primary breast cancer therapy, chemotherapy therapy sequencing, 214-215
Breast cancer patient advocacy, 120
Ductal carcinoma in situ, 247-250
Epithelial ovarian cancer treatment, 91, 92
Head and neck cancer, 364-365
Primary chemotherapy in surgically resectable breast cancer, 240-241
Primary invasive breast cancer surgery, 280-281
Prostate cancer, 165-178. See also Brachytherapy
Prostate cancer screening, 137

Radical mastectomy
Challenges to, 200

Radical prostatectomy
Prostate cancer, 137, 166

Reach to Recovery Program
Breast reconstruction, 290

Recurrence fears
Breast cancer patient advocacy, 122

Regional infusion therapy
Colorectal liver metastases, 58-60

Retroperitoneal lymph nodes
Epithelial ovarian cancer metastasis, 88

Retropubic technique
Brachytherapy (for prostate cancer), 167-168

S

Salivary gland treatment
Head and neck cancer, 363

Salvage chemotherapy
Epithelial ovarian cancer treatment (advanced stage), 95-96

Sexual functioning
Breast cancer patient advocacy, 121-122

Sonography
Ovarian cancer detection, 76-77
Transrectal ultrasound (TRUS), prostate cancer screening, 137, 138, 139, 154-155, 167

Staging
Chemoprevention, 37
Epithelial ovarian cancer treatment, 88-89, 90
Head and neck cancer, 354-355
Neuroblastoma, 184-185
Oral and oropharyngeal squamous cancers, 343-345
Ovarian cancer, 69 (Guest Editorial), 71, 72

Statistics, See Cancer Statistics

Surgical management
Brachytherapy, 166
Breast cancer, primary chemotherapy in surgically resectable breast cancer, 227-243
Breast reconstruction, 289-304
Colorectal metastases to liver, 50-62
Ductal carcinoma in situ, 247-250
Epithelial ovarian cancer treatment, 88-89
Head and neck cancer, 358-365
Primary invasive breast cancer, 279-288
Prophylactic mastectomy, 270-275
Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial)

T

Tamoxifen
Adjuvant systemic primary breast cancer therapy, 204, 216
Chemoprevention, 33
Epithelial ovarian cancer treatment, 94
Primary chemotherapy in surgically resectable breast cancer, 229
Prophylactic mastectomy alternatives, 275

Taxotere
Epithelial ovarian cancer treatment, 94

Thrombocytopenia
Epithelial ovarian cancer treatment, 95

Tobacco use prevention and cessation, 369-374
California Tobacco Control Program, 369-372
Overview, 369
Primary care physician role, 372-373

Toxicity
Adjuvant systemic primary breast cancer therapy, chemotherapy, 215-216
Adjuvant systemic primary breast cancer therapy, hormone therapy, 211-213

Transabdominal and transvaginal sonography
Ovarian cancer detection, 76-77

Transperineal technique
Brachytherapy (for prostate cancer), 168-169

Transrectal ultrasound (TRUS)
Prostate cancer screening, 137, 138, 139, 154-155, 167

Transverse retus abdominis musculocutaneous (TRAM) flap
Breast reconstruction techniques, 301-302

V

Vascular interruption
Colorectal liver metastases, 60

Vinblastin
Primary chemotherapy in surgically resectable breast cancer, 229

Vincristine
Primary chemotherapy in surgically resectable breast cancer, 231

Vital staining
Oral and oropharyngeal squamous cancers, 345-348

B

Bal DG, 369-374
Bilimoria MM, 263-278
Blasko JC, 165-178
Blumgart LH, 50-62
Bolden S, 8-30
Bonadonna G, 227-243
Bostwick J III, 289-304
Brawer MK, 148-164
Burch-Whitman C, 31-49
Buzdar AU, 199-226

C

Cherny NI, 64 (Letter)
Cohen AM, 50-62

D

Dilliolugil O, 134-147

F

Fong Y, 50-62

G

Ganz PA, 114-126
Garfinkel L, 5-7 (Guest Editorial)
Greenwald P, 31-49
Grimm PD, 165-178

H

Harris JR, 244-253
Hetelekidis S, 244-253
Holleb AI, 197-198 (Editorial)
Hortobagyi GN, 199-226

J

Jessup LM, 102-111
Johnston WW, 305-320

K

Kelloff G, 31-49
Kinne DW, 279-288
Kramer BS, 31-49

L

Lloyd JC, 369-374
Loré JM Jr, 325-327 (Guest Editorial)
Lydiatt W, 352-368

M

Mangalik A, 63-64 (Letter)
Manley MW, 369-374
Mashberg A, 328-351
Matthay KK, 179-192
McGuire WP, 88-101
Menck HR, 102-111
Moore MP, 279-288
Morrow M, 244-253, 263-278
Murphy GP, 102-111, 133 (Editorial)

O

Ohori M, 134-147

P

Park RC, 71-87
Patrick RL, 305-320
Petrek JA, 197-198 (Editorial)
Portenoy RK, 64 (Letter)
Porter AT, 165-178

Q

Qazi F, 88-101

R

Ragde H, 165-178
Reddy SM, 165-178

S

Salvadori B, 227-243
Samit A, 328-351
Scardino PT, 134-147
Schnitt SJ, 244-253
Shah JP, 352-368
Shingleton HM, 305-320
Slawin KM, 134-147
Smith RA, 305-320
Steele GD Jr, 102-111

T

Teneriello MG, 71-87
Tong T, 8-30

V

Valagussa P, 227-243

W

Winchester DP, 102-111, 261-262 (Guest Editorial)
Wingo PA, 8-30

Y

Young RC, 69-70 (Guest Editorial)

Z

Zucali R, 227-243